Beta-lactamases (β-lactamases) are enzymes produced by bacteria that provide multi-resistance to beta-lactam antibiotics such as penicillins, cephalosporins, cephamycins, monobactams and carbapenems (ertapenem), although carbapenems are relatively resistant to beta-lactamase. Beta-lactamase provides antibiotic resistance by breaking the antibiotics' structure. These antibiotics all have a common element in their molecular structure: a four-atom ring known as a beta-lactam (β-lactam) ring. Through hydrolysis, the enzyme lactamase breaks the β-lactam ring open, deactivating the molecule's antibacterial properties.
The American Society for Microbiology (ASM), originally the Society of American Bacteriologists, is a professional organization for scientists who study viruses, bacteria, fungi, algae, and protozoa as well as other aspects of microbiology. It was founded in 1899. The Society publishes a variety of scientific journals, textbooks, and other educational materials related to microbiology and infectious diseases. ASM organizes annual meetings, as well as workshops and professional development opportunities for its members.
Klebsiella pneumoniae is a Gram-negative, non-motile, encapsulated, lactose-fermenting, facultative anaerobic, rod-shaped bacterium. It appears as a mucoid lactose fermenter on MacConkey agar.
Multiple drug resistance (MDR), multidrug resistance or multiresistance is antimicrobial resistance shown by a species of microorganism to at least one antimicrobial drug in three or more antimicrobial categories. Antimicrobial categories are classifications of antimicrobial agents based on their mode of action and specific to target organisms. The MDR types most threatening to public health are MDR bacteria that resist multiple antibiotics; other types include MDR viruses, parasites.
Global Infectious Diseases and Epidemiology Online Network (GIDEON) is a web-based program for decision support and informatics in the fields of Infectious Diseases and Geographic Medicine. Due to the advancement of both disease research and digital media, print media can no longer follow the dynamics of outbreaks and epidemics as they emerge in "real time." As of 2005, more than 300 generic infectious diseases occur haphazardly in time and space and are challenged by over 250 drugs and vaccines. 1,500 species of pathogenic bacteria, viruses, parasites and fungi have been described. GIDEON works to combat this by creating a diagnosis through geographical indicators, a map of the status of the disease in history, a detailed list of potential vaccines and treatments, and finally listing all the potential species of the disease or outbreak such as bacterial classifications.
Antibiotic sensitivity testing or antibiotic susceptibility testing is the measurement of the susceptibility of bacteria to antibiotics. It is used because bacteria may have resistance to some antibiotics. Sensitivity testing results can allow a clinician to change the choice of antibiotics from empiric therapy, which is when an antibiotic is selected based on clinical suspicion about the site of an infection and common causative bacteria, to directed therapy, in which the choice of antibiotic is based on knowledge of the organism and its sensitivities.
In microbiology, the minimum inhibitory concentration (MIC) is the lowest concentration of a chemical, usually a drug, which prevents visible in vitro growth of bacteria or fungi. MIC testing is performed in both diagnostic and drug discovery laboratories.
Combined immune deficiencies (CIDs) are a diverse group of inherited immune disorders characterized by impaired T lymphocyte development, function, or both, with variable B cell defects. The primary clinical manifestation of CID is infection susceptibility. Clinical manifestations of combined immunodeficiencies vary greatly, ranging from diarrhea and sinus infections to opportunistic infections caused by mycobacteria, fungi, and vaccination reactions resulting in localized to systemic symptoms.
Beta-lactamases are a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. In bacterial resistance to beta-lactam antibiotics, the bacteria have beta-lactamase which degrade the beta-lactam rings, rendering the antibiotic ineffective. However, with beta-lactamase inhibitors, these enzymes on the bacteria are inhibited, thus allowing the antibiotic to take effect. Strategies for combating this form of resistance have included the development of new beta-lactam antibiotics that are more resistant to cleavage and the development of the class of enzyme inhibitors called beta-lactamase inhibitors. Although β-lactamase inhibitors have little antibiotic activity of their own, they prevent bacterial degradation of beta-lactam antibiotics and thus extend the range of bacteria the drugs are effective against.
Ceftolozane/tazobactam, sold under the brand name Zerbaxa, (Merck) is a fixed-dose combination antibiotic medication used for the treatment of complicated urinary tract infections and complicated intra-abdominal infections in adults. Ceftolozane is a cephalosporin antibiotic, developed for the treatment of infections with gram-negative bacteria that are resistant to conventional antibiotics. It was studied for urinary tract infections, intra-abdominal infections and ventilator-associated bacterial pneumonia.
Sherwood Leslie Gorbach is an Emeritus Professor at Tufts University School of Medicine. He was editor-in-chief of the journal Clinical Infectious Diseases from 2000 to 2016.
Karen Bush is an American biochemist. She is a professor of Practice in Biology Emerita at Indiana University Bloomington and served as the interim director of the Biotechnology program from 2019-2022. Bush conducts research focusing on the activity of novel antimicrobial agents against Gram-negative bacteria and bacterial resistance mechanisms to beta-lactam antibiotics.
Allison Joan McGeer is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.
Robin Patel is a Canadian born microbiologist and Elizabeth P. and Robert E. Allen Professor of Individualized Medicine, a Professor of Microbiology, and a Professor of Medicine at the Mayo Clinic. She is widely recognized as a leader in the field of clinical microbiology and has held a variety of leadership positions including 2019–2020 President of the American Society for Microbiology (ASM) and Director of the Antibacterial Resistance Leadership Group (ARLG) Laboratory Center of the National institutes of Health. She is currently the Vice Chair of Education in the Department of Laboratory Medicine and Pathology at the Mayo Clinic, and Director of the Mayo Clinic's Infectious Diseases Research Laboratory, where she studies biofilms, antimicrobial resistance, periprosthetic joint infection and diagnostic testing of bacteria.
David R. Murdoch is a New Zealand academic specialising in paediatric infectious diseases, especially pneumonia. He has also worked on Legionnaires' disease and has advised the Oxford University vaccine group and the New Zealand government on COVID-19. Murdoch served as Vice-Chancellor of the University of Otago between February 2022 and June 2023.
Tania Sorrell is an Australian infectious disease physician who is a Professor and Director of the Marie Bashir Institute for Infectious Diseases and Biosecurity at the University of Sydney. She serves as Chair of the National Health and Medical Research Council Research Translation Faculty Steering Group on New and Emerging Health Threats. She is interested in the diagnosis, prevention and treatment of infectious diseases.
Anne Louise Wyllie is a New Zealand microbiologist who was the lead author of a 2020 research article which led to the development of the SalivaDirect PCR method of testing saliva for SARS-CoV-2, the virus that causes COVID-19. She has also worked on community studies to better understand pneumococcal disease. She is a research scientist in epidemiology with the Public Health Modeling Unit at Yale University.
Carey-Ann Burnham is a clinical microbiologist, and a professor of Pathology and Immunology, Molecular Microbiology, Pediatrics and Medicine in Washington University School of Medicine in St. Louis. She is an elected fellow of the American Academy of Microbiology.
Aztreonam/avibactam, sold under the brand name Emblaveo, is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections. Drug resistance to the combination has been reported.
Helen Mary Heffernan is a New Zealand microbiologist, specialising in antibiotic resistance. In 2020, she was appointed a Companion of the New Zealand Order of Merit, for services to health. The Institute of Environmental Science and Research awarded Heffernan their Lifetime Achievement Award in 2018.
